Literature DB >> 20561764

Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.

A Ross1, A Sardi, C Nieroda, B Merriman, V Gushchin.   

Abstract

BACKGROUND: Appendiceal malignancies with peritoneal spread have been successfully treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study is to clarify the utility of common tumor markers in selecting patients for the combined treatment.
METHODS: Data on 56 patients with appendiceal neoplasms treated with CRS and HIPEC were prospectively collected. Chi square test was used to analyze a link between common tumor markers and completeness of cytoreduction score (CC score) and preoperative peritoneal cancer index score (PCI score). Cox proportional hazard model was used to perform survival analysis.
RESULTS: Forty-two patients were alive after 3 years of follow-up. Hazard ratio of disease related death was 5.6 (95% CI, 1.8-17.2) among patients with high CC score as compared to those with low CC score. Number of abnormal tumor markers (0 vs 1/2/3) correlated with PCI score 16.2 vs 32.5 (p < 0.001) but not with completeness of cytoreduction or survival. The 3-year survival rates in patients with normal vs abnormal CA 125 levels were 83% vs 52%(p = 0.003).
CONCLUSIONS: Multiple abnormal tumor markers were not useful as an exclusion criterion for patients undergoing CRS. Elevation in CA 125 was an important indicator of survival in these patients. Complete cytoreduction was crucial for long-term survival. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561764     DOI: 10.1016/j.ejso.2010.05.024

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

Review 1.  Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.

Authors:  Russell N Low
Journal:  J Gastrointest Oncol       Date:  2016-02

2.  Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy.

Authors:  Ju-Li Koh; Winston Liauw; Terence Chua; David L Morris
Journal:  J Gastrointest Oncol       Date:  2013-06

3.  Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Emel Canbay; Haruaki Ishibashi; Shouzou Sako; Akiyoshi Mizumoto; Masamitsu Hirano; Masumi Ichinose; Nobuyuki Takao; Yutaka Yonemura
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

4.  Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin.

Authors:  Patrick L Wagner; Frances Austin; Magesh Sathaiah; Deepa Magge; Ugwuji Maduekwe; Lekshmi Ramalingam; Heather L Jones; Matthew P Holtzman; Steven A Ahrendt; Amer H Zureikat; James F Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2012-09-01       Impact factor: 5.344

Review 5.  The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Tumors and Colorectal Adenocarcinomas.

Authors:  Michael Kuncewitch; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos
Journal:  Clin Colon Rectal Surg       Date:  2018-09-04

Review 6.  Peritoneal Metastases from Appendiceal Cancer.

Authors:  Konstantinos I Votanopoulos; Perry Shen; Aleksander Skardal; Edward A Levine
Journal:  Surg Oncol Clin N Am       Date:  2018-07       Impact factor: 3.495

7.  Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei.

Authors:  Lei Liang; Jingyang Fang; Xuedi Han; Xichao Zhai; Yan Song; Yiyan Lu; Qian Zhang; Ruiqing Ma
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

8.  Radiomics analysis based on CT's greater omental caking for predicting pathological grading of pseudomyxoma peritonei.

Authors:  Nan Zhou; Ruixue Dou; Xichao Zhai; Jingyang Fang; Jiajun Wang; Ruiqing Ma; Jingxu Xu; Bin Cui; Lei Liang
Journal:  Sci Rep       Date:  2022-03-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.